Marinus Pharmaceuticals, Inc.

Marinus Pharmaceuticals, Inc. is a risky bet given it's low Altman Z-score. Companies with a low Altman Z-score have a higher chance of going bankrupt within the next 2 years. Marinus Pharmaceuticals, Inc. is not a good value stock. Marinus Pharmaceuticals, Inc. is not very popular among insiders. Marinus Pharmaceuticals, Inc. is a mediocre stock to choose.

Marinus Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the identification an...

News

Marinus Pharmaceuticals Announces Agenda and Speakers for Investor & Analyst Day on September 20, 2024

Business Wire Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced agenda topics and speakers...\n more…

Marinus Pharmaceuticals to Present at the 2024 Cantor Global Healthcare Conference

Marinus Pharmaceuticals to Host Investor and Analyst Day on Friday, September 20, 2024

Business Wire Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, will host an Investor and Analyst Day on...\n more…

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Simply Wall St Marinus Pharmaceuticals, Inc. ( NASDAQ:MRNS ) missed earnings with its latest quarterly results, disappointing...\n more…

Ladenburg gets more bearish on Marinus Pharmaceuticals, downgrades shares

The Fly See the rest of the story here.\n\nthefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...\n more…

Marinus Pharmaceuticals, Inc. 2024 Q2 - Results - Earnings Call Presentation

SeekingAlpha Marinus Pharmaceuticals, Inc. 2024 Q2 - Results - Earnings Call Presentation...\n more…